

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. to 35. (CANCELED)

36. *(previously presented)*: A method of treating systemic inflammatory response syndrome (SIRS) in a human subject in need thereof, the method comprising:

- (a) selecting a human subject having a risk genotype for SIRS, which subject has one of more of the following genotypes at one or more of the following positions:
  - (i) CC or CT at 4732 of SEQ ID NO:1;
  - (ii) TT or TC at 4054 of SEQ ID NO:2,
  - (iii) AA or AG at 2418 of SEQ ID NO:1, or
  - (iv) a genotype in linkage disequilibrium (LD) with position 4732; 4054; and 2418 as follows:
    - (1) for sites in LD with position 4732 of SEQ ID NO:1: AA or AG at 4813, GG or GA at 6379, AA or AG at 6762, CC or C- at 7779, TT or TC at 8058, TT or TG at 8915 or TT or TC at 12228 of SEQ ID NO:1;
    - (2) for sites in LD with position 4054 of SEQ ID NO:2: CC or CT at 2973, GG or GA at 3063, GG or GC at 3402, TT or TC at 4946, TT or TC at 5515 or GG or GC at 6196 of SEQ ID NO:2; or
    - (3) for sites in LD with position 2418 of SEQ ID NO:1: TT or TC at 1386, AA or AT at 2583 or TT or TC at 3920 in SEQ ID NO:1; or
- (v) a combination of genotypes in SEQ ID NO:1 which are in LD with position 4732 in SEQ ID NO:1 selected from the group of genotypes at positions consisting of:
  - (1) CC or CA at 9198 and AA or AG at 5867;
  - (2) CC or CA at 9198 and GG or GC at 4800;
  - (3) AA or AG at 3220 and AA or AG at 5867; and
  - (4) AA or AG at 3220 and GG or GC of 4800;
- (vi) a combination of genotypes in SEQ ID NO:1 which are in LD with position 2418 in SEQ ID NO:1, selected from the group of genotypes at positions consisting of:

- (1) AA or AG at 5867 and TT or TC at 2405;
- (2) AA or AG at 5867 and AA or AG at 4919;
- (3) AA or AG at 5867 and TT or TC at 4956;
- (4) AA or AG at 5867 and CC or CT at 6187;
- (5) AA or AG at 5867 and TT or TC at 12109;
- (6) GG or GC at 4800 and TT or TC at 2405;
- (7) GG or GC at 4800 and AA or AG at 4919;
- (8) GG or GC at 4800 and TT or TC at 4956;
- (9) GG or GC at 4800 and CC or CT at 6187; and
- (10) GG or GC at 4800 and TT or TC at 12109, and

(b) administering to said human subject selected in (a) an activated protein C.

**37 to 43: CANCELED**

44. *(previously presented):* The method at claim 36, further comprising determining the subject's APACHE II score as an assessment of subject risk.

45. *(previously presented):* The method of claim 36, further comprising determining the number of organ system failures for the subject as an assessment of subject risk.

46. *(previously presented):* The method of claim 44, wherein, an APACHE II score  $\geq 25$  is indicative of increased risk.

47. *(previously presented):* The method of claim 45, wherein two or more organ system failures are indicative of increased subject risk.

**48. to 59. (CANCELED)**

60. *(previously presented):* The method of claim 36, wherein the genotype of the subject is indicative of an increased risk of poor outcome from the SIRS .

61. *(previously presented):* The method of claim 60, wherein the subject who has an increased risk of poor outcome from SIRS is preferentially selected for administration of the activated protein C.

**62 to 67. (CANCELED)**

68. *(previously presented)*: The method of claim 36, wherein the activated protein C is drotrecogin alfa activated.

**69 to 87:** (CANCELED)

88. *(previously presented)*: The method of claim 36, wherein the risk genotype is located at a polymorphic site at one or both positions 4732 of SEQ ID NO:1 and 4054 of SEQ ID NO:2.

**89. to 91.** (CANCELED)

92. *(previously presented)*: The method of claim 36, wherein the human subject has sepsis.

93. *(previously presented)*: The method of claim 36, wherein the human subject has septic shock.